Replies to post #99210 on Biotech Values

[DewDiligence]

GRFS, the company that acquired Talecris in 2010, is apparently still pursuing inhaled AAT; this phase-2 study was started in 2012:

http://www.clinicaltrials.gov/ct2/show/NCT01684410